Gallmetzer Healthcare SpA

As of December 31, 2025, Gallmetzer Healthcare SpA carries a market capitalization of 56.00M, placing it among publicly traded companies globally. Its enterprise value stands at 65.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Gallmetzer Healthcare SpA has 16.00M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 0.95, and the price-to-book ratio stands at 7.06.

As of December 31, 2025, Gallmetzer Healthcare SpA trades at an EV/EBITDA multiple of 59.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 692.61 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 65.07M versus a market cap of 56.00M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Gallmetzer Healthcare SpA maintains a current ratio of 0.60, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 112.78, indicating elevated leverage, while an interest coverage ratio of 2.62 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Gallmetzer Healthcare SpA recorded 148,889.00 in income tax expense. The company reported a pretax loss of -461,148.00 and -555,385.00 in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on September 24, 2026.

Over the twelve months ended December 31, 2025, Gallmetzer Healthcare SpA generated 59.23M in revenue and converted that into -555,385.00 in net income, yielding earnings per share of -0.04. EBITDA reached 1.09M, while operating income came in at 56,226.00.

As of December 31, 2025, Gallmetzer Healthcare SpA holds 119,444.00 in cash and equivalents against 9.08M in total debt, resulting in a net debt position of 8.96M. Total book value stands at 7.94M, with working capital of -9.94M providing operational flexibility.

Gallmetzer Healthcare SpA produced 406,428.00 in operating cash flow over the twelve months ended December 31, 2025. After subtracting -527,044.00 in capital expenditures, free cash flow totaled -120,616.00 - equivalent to -0.01 per share.

Over the twelve months ended December 31, 2025, Gallmetzer Healthcare SpA posted a gross margin of 14.84, reflecting its pricing power and cost economics. The operating margin of 0.09 and net profit margin of -0.94 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -0.22: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.84, meaning Gallmetzer Healthcare SpA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, Gallmetzer Healthcare SpA has an Altman Z-Score of 4.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.